NCT07843264 PPI Dosing Per CYP2C19 Genotype
| NCT ID | NCT07843264 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of Florida |
| Condition | Gastroesophageal Reflux Disease With Esophagitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-11-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 200 participants in total. It began in 2026-11-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is being done to determine if the dosing of proton pump inhibitor (PPI) medication based on CYP2C19 genotype-derived phenotype leads to improved healing of erosive esophagitis compared to conventional PPI medication dosing.
Eligibility Criteria
Inclusion Criteria: * age ≥ 18 years * diagnosis of Gastroesophageal Reflux Disease (GERD) scheduled for an esophagogastroduodenoscopy (EGD) * patients diagnosed with Erosive Esophagitis on endoscopy (EGD). Exclusion Criteria: * age \<18 years * diagnosed with non-erosive reflux disease (NERD) * pregnancy
Contact & Investigator
Ruchir Puri, MD
PRINCIPAL INVESTIGATOR
University of Florida
Frequently Asked Questions
Who can join the NCT07843264 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Gastroesophageal Reflux Disease With Esophagitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07843264 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07843264 currently recruiting?
Yes, NCT07843264 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Florida to inquire about joining.
Where is the NCT07843264 trial being conducted?
This trial is being conducted at Jacksonville, United States.
Who is sponsoring the NCT07843264 clinical trial?
NCT07843264 is sponsored by University of Florida. The principal investigator is Ruchir Puri, MD at University of Florida. The trial plans to enroll 200 participants.